Gilead Acquires Sagimet Biosciences for $275M
Ticker: SGMT · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1400118
Sentiment: bullish
Topics: acquisition, merger, biotech, healthcare
Related Tickers: GILD
TL;DR
Gilead buying Sagimet for $275M, deal expected Q4 2024.
AI Summary
Sagimet Biosciences Inc. announced on August 14, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for $275 million in cash. This transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by Gilead Sciences could significantly impact Sagimet's pipeline and potentially accelerate the development of new treatments for liver diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and there's always a risk of regulatory hurdles or unforeseen issues that could delay or prevent the deal from closing.
Key Numbers
- $275 million — Acquisition Price (Cash amount Gilead Sciences is paying for Sagimet Biosciences.)
- Q4 2024 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Company filing the report and being acquired
- Gilead Sciences, Inc. (company) — Acquiring company
- $275 million (dollar_amount) — Purchase price for Sagimet Biosciences
- August 14, 2024 (date) — Date of the definitive agreement and report filing
- fourth quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Gilead Sciences acquiring Sagimet Biosciences?
While not explicitly stated as the primary reason, the acquisition is likely driven by Sagimet's pipeline, particularly its work in liver diseases, which aligns with Gilead's strategic interests.
Are there any specific regulatory approvals required for this acquisition?
The filing mentions 'customary closing conditions,' which typically include regulatory approvals, but specific details are not provided in this summary.
What is Sagimet Biosciences' former company name?
Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc., with a name change date of May 21, 2007.
What is Sagimet Biosciences' principal executive office address?
Sagimet Biosciences Inc.'s principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
What is the SIC code for Sagimet Biosciences?
The Standard Industrial Classification (SIC) code for Sagimet Biosciences Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-14 08:06:04
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2421625d1_8k.htm (8-K) — 30KB
- tm2421625d1_ex99-1.htm (EX-99.1) — 57KB
- tm2421625d1_ex99-2.htm (EX-99.2) — 45KB
- tm2421625d1_ex99-2img001.jpg (GRAPHIC) — 129KB
- tm2421625d1_ex99-2img002.jpg (GRAPHIC) — 321KB
- tm2421625d1_ex99-2img003.jpg (GRAPHIC) — 137KB
- tm2421625d1_ex99-2img004.jpg (GRAPHIC) — 177KB
- tm2421625d1_ex99-2img005.jpg (GRAPHIC) — 142KB
- tm2421625d1_ex99-2img006.jpg (GRAPHIC) — 122KB
- tm2421625d1_ex99-2img007.jpg (GRAPHIC) — 112KB
- tm2421625d1_ex99-2img008.jpg (GRAPHIC) — 123KB
- tm2421625d1_ex99-2img009.jpg (GRAPHIC) — 106KB
- tm2421625d1_ex99-2img010.jpg (GRAPHIC) — 121KB
- tm2421625d1_ex99-2img011.jpg (GRAPHIC) — 65KB
- tm2421625d1_ex99-2img012.jpg (GRAPHIC) — 130KB
- tm2421625d1_ex99-2img013.jpg (GRAPHIC) — 129KB
- tm2421625d1_ex99-2img014.jpg (GRAPHIC) — 100KB
- tm2421625d1_ex99-2img015.jpg (GRAPHIC) — 86KB
- tm2421625d1_ex99-2img016.jpg (GRAPHIC) — 118KB
- tm2421625d1_ex99-2img017.jpg (GRAPHIC) — 149KB
- tm2421625d1_ex99-2img018.jpg (GRAPHIC) — 93KB
- tm2421625d1_ex99-2img019.jpg (GRAPHIC) — 130KB
- tm2421625d1_ex99-2img020.jpg (GRAPHIC) — 96KB
- tm2421625d1_ex99-2img021.jpg (GRAPHIC) — 91KB
- tm2421625d1_ex99-2img022.jpg (GRAPHIC) — 104KB
- tm2421625d1_ex99-2img023.jpg (GRAPHIC) — 97KB
- tm2421625d1_ex99-2img024.jpg (GRAPHIC) — 130KB
- tm2421625d1_ex99-2img025.jpg (GRAPHIC) — 141KB
- tm2421625d1_ex99-2img026.jpg (GRAPHIC) — 141KB
- tm2421625d1_ex99-2img027.jpg (GRAPHIC) — 147KB
- tm2421625d1_ex99-2img028.jpg (GRAPHIC) — 64KB
- tm2421625d1_ex99-2img029.jpg (GRAPHIC) — 73KB
- tm2421625d1_ex99-2img030.jpg (GRAPHIC) — 107KB
- tm2421625d1_ex99-2img031.jpg (GRAPHIC) — 113KB
- tm2421625d1_ex99-2img032.jpg (GRAPHIC) — 152KB
- tm2421625d1_ex99-2img033.jpg (GRAPHIC) — 139KB
- tm2421625d1_ex99-2img034.jpg (GRAPHIC) — 177KB
- tm2421625d_ex99-1img001.jpg (GRAPHIC) — 18KB
- 0001104659-24-089340.txt ( ) — 6186KB
- sgmt-20240814.xsd (EX-101.SCH) — 3KB
- sgmt-20240814_lab.xml (EX-101.LAB) — 33KB
- sgmt-20240814_pre.xml (EX-101.PRE) — 22KB
- tm2421625d1_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated August 14, 2024 99.2 Investor Presentation of Sagimet Biosciences Inc., dated August 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: August 14, 2024 By: /s/ David Happel David Happel Chief Executive Officer